



Characteristics and outcomes of patients with right-sided endocarditis undergoing cardiac surgery

Carolyn Weber, Asmae Gassa, Kaveh Eghbalzadeh, Julia Merkle, Ilija Djordjevic, Johanna Maier, Anton Sabashnikov, Antje-Christin Deppe, Elmar W. Kuhn, Parwis B. Rahmanian, Oliver J. Liakopoulos, Thorsten Wahlers

Department of Cardiothoracic Surgery, University of Cologne, Cologne, Germany

Correspondence to: Dr. Carolyn Weber, Department of Cardiothoracic Surgery, University of Cologne, Kerpener Strasse 62, 50937 Cologne, Germany. Email: carolyn.weber@uk-koeln.de.

Background: There has been an increasing incidence of right-sided infective endocarditis (RSIE) due to the global rise of intravenous drug use (IVDU) and an increasing number of implantable cardiac electronic devices and central venous catheters. Our aim was to investigate differences in the clinical presentation, microbiological findings and prognosis of patients undergoing surgery for RSIE compared to left-sided infective endocarditis (LSIE).

Methods: Relevant clinical data of all 432 consecutive patients undergoing valve surgery for infective endocarditis (IE) at our institution between January 2009 and December 2018 were retrospectively analyzed. Acquired data included patients' demographic and preoperative comorbidities, manifestation of IE according to the recently modified Duke Criteria, perioperative data and relevant clinical outcomes.

Results: A total of 403 patients (93.3%) underwent surgery for LSIE and twenty-nine patients (6.7%) for RSIE. Eleven patients with RSIE (37.9%) showed a concomitant left-sided infection. Compared to LSIE, RSIE patients were significantly younger [47.5 (40.4–69.3) *vs.* 65.1 (53.7–74.6); $P=0.008$] and presented with less comorbidities such as hypertension (41.4% *vs.* 65.3%; $P=0.010$) and coronary artery disease (6.9% *vs.* 29.0%; $P=0.010$). Rates of IVDU (34.5% *vs.* 4.5%; $P<0.001$), human immunodeficiency virus (HIV) (10.3% *vs.* 1.7%; $P=0.023$) and hepatitis C virus (HCV) infection (24.1% *vs.* 5.2%; $P=0.001$) were greater in RSIE. The proportion of *Staphylococcus aureus* IE was significantly higher in RSIE compared to LSIE (37.9% *vs.* 21.1%; $P=0.035$). 30-day mortality was 6.9% after surgery for RSIE compared to 14.6% after operation for LSIE ($P=0.372$).

Conclusions: Patients undergoing surgery for RSIE compared to LSIE presented with a higher rate of pulmonary septic emboli, more *Staphylococcus aureus* infections and larger vegetations. Larger multicenter prospective trials are needed to provide more reliable data on the clinical profile of these patients, in order to determine optimal surgical management.

Keywords: Endocarditis; infective endocarditis (IE); right-sided IE



Submitted Apr 29, 2019. Accepted for publication Jul 18, 2019.

doi: 10.21037/acs.2019.08.02

View this article at: <http://dx.doi.org/10.21037/acs.2019.08.02>

Introduction

Right-sided infective endocarditis (RSIE) accounts for only 5–10% of all cases of infective endocarditis (IE) (1,2). However, an increase in the incidence of RSIE has recently been reported, primarily attributable to the global rise in

the number of intravenous drug use (IVDU), along with an increased number of patients with cardiac implantable electronic devices (CIED) and a rising number of central venous catheters in clinical care (1,3-5). The vast majority of RSIE cases involve the tricuspid valve, with pulmonary valve involvement accounting for less than 10% of all right-

sided cases (6).

The diagnosis of RSIE is frequently delayed, as right-sided murmurs often remain undetected and the usual presenting symptoms of persistent fever associated with pulmonary manifestations can be misdiagnosed as a respiratory tract infection (1,7). Consequently, the delay in timely diagnosis and initiation of appropriate antimicrobial therapy, leads to further complications, such as pulmonary infarcts, pulmonary abscesses, lung emphysema and rarely, pneumothorax (3,8).

Between 5–40% of patients with RSIE require surgical intervention (9–12), with reported operative mortalities between 0–15% for patients with isolated tricuspid valve IE (5,12,13). However, timing of surgery for RSIE is less clear than for left-sided infective endocarditis (LSIE). In RSIE, surgical treatment is mainly considered in patients with large vegetations, recurrent septic pulmonary emboli, persistent infection not responding to antibiotic therapy or worsening tricuspid regurgitation contributing to deteriorating right heart failure (5,10).

Given the low incidence of RSIE, available data of patients undergoing surgery for RSIE are scarce. Our aim was to analyze the clinical characteristics and predisposing risk factors of patients undergoing surgery for RSIE. A second objective was to investigate differences in the clinical presentation, microbiological findings and prognosis of surgical patients with RSIE compared to LSIE.

Methods

Study population

We retrospectively analyzed the clinical data of all 432 consecutive patients undergoing valve surgery for IE at our institution between January 2009 and December 2018. Acquired data included patients' demographics and preoperative comorbidities, manifestation of IE according to the recently modified Duke Criteria (14) (echocardiographic and microbiological data), perioperative data [timing of operation, cardiopulmonary bypass time (CPB) and crossclamp time] and relevant clinical outcomes. Long-term follow-up was obtained by review of hospital records and interview of patients' physicians. The follow-up time for survival was measured from the date of operation to either the date of death or the date of the last contact with the patient. The study protocol was approved by the institutional review board. Individual informed consent was waived due to the retrospective nature of the collected data.

Operative procedure

Cardiac surgery for IE was indicated according to the recent European Society of Cardiology (ESC) guidelines for the management of IE (15) and performed as previously described (16). The type of surgery was performed according to the surgeon's preference and the extent of infection, with the aim of achieving radical debridement of infected tissue. Intraoperative transesophageal echocardiography was performed in all patients. Hemodynamic, catecholamine and blood transfusion management was administered at the discretion of the attending surgeon and anesthesiologist.

Statistical analysis

Unless otherwise indicated, continuous variables were described using mean values $\pm$ standard deviation (SD) or median [interquartile range (IQR)] according to the normality of their distribution and compared using unpaired *t*-test or Mann-Whitney U test as appropriate. Discrete variables were reported as percentages and tested by chi-squared test or, when validity conditions were not satisfied, by Fisher's exact test. Missing data were not imputed and assumed to be missing at random. All reported P values are two-sided and considered statistically significant if ≤ 0.05 . Statistical analyses were performed using SPSS Statistics Version 25 (IBM Corp., Armonk, NY, USA).

Results

Preoperative characteristics

The preoperative clinical profile of our surgical IE population is summarized in *Table 1*. A total of 403 patients (93.3%) underwent surgery for LSIE and twenty-nine patients (6.7%) for RSIE. Patients undergoing surgery for RSIE were significantly younger [47.5 (40.4–69.3) *vs.* 65.1 (53.7–74.6); $P=0.008$] and presented with less comorbidities, such as hypertension (41.4% *vs.* 65.3%; $P=0.010$) and coronary artery disease (6.9% *vs.* 29.0%; $P=0.010$). Although not statistically significant, there was a trend towards less diabetes mellitus (13.8% *vs.* 27.8%; $P=0.100$), peripheral artery disease (3.4% *vs.* 8.2%; $P=0.310$) and preoperative stroke (6.9% *vs.* 13.2%; $P=0.293$) in RSIE patients. Conversely, smoking was more prevalent in RSIE (37.9% *vs.* 21.3%; $P=0.039$). EuroSCORE II was lower in RSIE [6.0 (4.0–9.5)] compared to LSIE [8.0 (5.0–11.0); $P=0.019$].

In contrast to the lower rate of comorbidities, patients

Table 1 Characteristics of patients undergoing surgery for left- versus right-sided IE

Characteristics	All patients (n=432)	LSIE (n=403)	RSIE (n=29)	P value
Patients' demographic and preoperative characteristics				
Age	64.7 (51.8–73.6)	65.1 (53.7–74.6)	47.5 (40.4–69.3)	0.008
Sex				
Male	327 (75.7)	307 (76.2)	20 (69.0)	0.382
Female	105 (24.3)	96 (23.8)	9 (31.0)	0.382
BMI	25.6 (23.4–28.3)	25.7 (23.5–28.4)	24.8 (22.5–27.7)	0.403
BSA	1.97 (1.82–2.12)	1.97 (1.82–2.12)	1.91 (1.71–2.11)	0.268
Hypertension	275 (63.7)	263 (65.3)	12 (41.4)	0.010
Diabetes	116 (26.9)	112 (27.8)	4 (13.8)	0.100
Hyperlipidemia	118 (27.3)	114 (28.3)	4 (13.8)	0.091
Smoking	97 (22.5)	86 (21.3)	11 (37.9)	0.039
COPD	41 (9.5)	38 (9.4)	3 (10.3)	0.872
Peripheral artery disease	34 (7.9)	33 (8.2)	1 (3.4)	0.310
Pulmonary hypertension	48 (11.1)	45 (11.2)	3 (10.3)	0.891
Preoperative AKI	248 (57.4)	233 (57.8)	15 (51.7)	0.522
Preoperative stroke	55 (12.7)	53 (13.2)	2 (6.9)	0.293
Coronary artery disease	119 (27.5)	117 (29.0)	2 (6.9)	0.010
LVEF				
≥50%	327 (75.7)	307 (76.2)	20 (69.0)	0.382
≥30% to 50%	96 (22.2)	87 (21.6)	9 (31.0)	0.237
<30%	9 (2.1)	9 (2.2)	0 (0)	0.912
EuroSCORE II	8.0 (5.0–11.0)	8.0 (5.0–11.0)	6.0 (4.0–9.5)	0.019
Risk factors				
History of endocarditis	26 (6.0)	23 (5.7)	3 (10.3)	0.351
Congenital heart disease	13 (3.0)	10 (2.5)	3 (10.3)	0.049
Alcohol abuse	40 (9.3)	37 (9.2)	3 (10.3)	0.837
Intravenous drug use	28 (6.5)	18 (4.5)	10 (34.5)	<0.001
HIV	10 (2.3)	7 (1.7)	3 (10.3)	0.023
Active hepatitis				
HAV	–	–	–	
HBV	3 (0.7)	3 (0.7)	0 (0)	0.518
HCV	28 (6.5)	21 (5.2)	7 (24.1)	0.001
Immunosuppression	8 (1.9)	7 (1.7)	1 (3.4)	0.551
History of neoplasm	44 (10.2)	42 (10.4)	2 (6.9)	0.524
Septic embolism				
Brain	95 (22.0)	92 (22.8)	3 (10.3)	0.117
Lungs	13 (3.0)	5 (1.2)	8 (27.6)	<0.001
Spleen	41 (9.5)	39 (9.7)	2 (6.9)	0.607
Kidney	17 (3.9)	17 (4.2)	0 (0)	0.120
Symptoms				
Fever	279 (64.6)	258 (64.0)	21 (72.4)	0.361
Preoperative catecholamines	56 (13.0)	56 (13.9)	0 (0)	0.004
Preoperative ventilation	69 (16.0)	68 (16.9)	1 (3.4)	0.026
Data presented as median (IQR) or number (percent), respectively. AKI, acute kidney injury; BMI, body mass index; BSA, body surface area; COPD, chronic obstructive pulmonary disease; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IE, infective endocarditis; IQR, interquartile range; LSIE, left-sided infective endocarditis; LVEF, left ventricular ejection fraction; RSIE, right-sided infective endocarditis.				

Table 2 Echocardiographic and perioperative data of patients undergoing surgery for left- compared to right-sided IE

Variable	All patients (n=432)	LSIE (n=403)	RSIE (n=29)	P value
Echocardiographic findings				
Vegetation	346 (80.1)	320 (79.4)	26 (89.7)	0.196
Vegetation lengths (cm)	1.5 [1.0–2.0]	1.5 [1.0–2.0]	2.2 [1.8–2.9]	0.007
Perivalvular infection				
Abscess	143 (33.1)	138 (34.2)	5 (17.2)	0.060
Perforation	103 (23.8)	99 (24.6)	4 (13.8)	0.189
Fistula	14 (3.2)	13 (3.2)	1 (3.4)	0.948
Perioperative data				
Duration of preoperative antibiotics (days)	12.0 [6.0–20.0]	12.0 [6.0–20.0]	23.0 [7.8–29.3]	0.091
Days between diagnosis and operation	9.0 [4.0–18.0]	9.0 [2.0–17.0]	23.0 [5.0–35.0]	0.006
Timing of operation				
Emergent (<24 h)	30 (6.9)	29 (7.2)	1 (3.4)	0.443
Urgent (24–72 h)	47 (10.9)	47 (11.7)	0 (0)	0.161
Elective	355 (82.2)	327 (81.1)	28 (96.6)	0.036
Operation time (min)	205 [159–260]	205 [160–262]	204 [144–240]	0.162
CPB time (min)	115 [86–154]	114 [86–157]	120 [64–135]	0.251
Crossclamp time (min)	75 [56–100]	75 [57–100]	74 [47–96]	0.290

Data presented as median [IQR] or number (percent), respectively. CPB, cardiopulmonary bypass; IE, infective endocarditis; LSIE, left-sided infective endocarditis; RSIE, right-sided infective endocarditis.

with RSIE presented with more risk factors for IE. Hence, higher rates of IVDU (34.5% *vs.* 4.5%; $P<0.001$), HIV (10.3% *vs.* 1.7%; $P=0.023$) and HCV infection (24.1% *vs.* 5.2%; $P=0.001$) were more frequently diagnosed in RSIE. In addition, congenital heart disease was more prevalent in RSIE compared to LSIE (10.3% *vs.* 2.5%; $P=0.049$).

RSIE patients suffered from more septic pulmonary emboli (27.6% *vs.* 1.2%; $P<0.001$), whereas LSIE patients presented with more severe manifestation of disease, reflected by greater preoperative catecholamine requirements (0% *vs.* 13.9%; $P=0.004$) and preoperative ventilation (3.4% *vs.* 16.9%; $P=0.026$).

IE manifestation

A total of 403 patients underwent surgery for LSIE. Only twenty-nine patients in the cohort were diagnosed with RSIE, including twenty-seven cases of tricuspid valve infection (93.1%) and two cases of pulmonary valve

infection (6.9%). In the RSIE group, eleven patients (37.9%) showed concomitant left-sided infection: six patients were diagnosed with concomitant aortic involvement and four patients with concomitant mitral valve involvement. One patient was operated due to RSIE with concomitant aortic and mitral valve IE.

Preoperative echocardiography revealed significantly larger vegetations in patients with RSIE compared to LSIE [2.2 (1.8–2.9) *vs.* 1.5 (1.0–2.0) cm; $P=0.007$]. Perivalvular infection was comparable in both groups (Table 2).

Microbiological findings are depicted in Figure 1. The three most detected causative microorganisms were *Staphylococcus aureus*, *Streptococcus spp.* and *Enterococcus spp.* The proportion of *Staphylococcus aureus* IE was significantly higher in RSIE compared to LSIE (37.9% *vs.* 21.1%; $P=0.035$).

With regard to the timing of operation, cardiac surgery for RSIE was performed later than in LSIE. Hence, the time between diagnosis and operation was significantly




Figure 1 Distribution of causative microorganisms in patients undergoing surgery for LSIE compared to RSIE. LSIE, left-sided infective endocarditis; RSIE, right-sided infective endocarditis. * $P=0.035$.

longer [23.0 (5.0–35.0) *vs.* 9.0 (2.0–17.0) days; $P=0.006$] and the proportion of elective surgery higher (96.6% *vs.* 81.1%; $P=0.036$). There was no difference in the duration of operation, reflected in similar operation, cardiopulmonary bypass (CPB) and crossclamp times (*Table 2*).

Postoperative clinical outcomes

Postoperative clinical outcomes are summarized in *Table 3*. There was no statistical difference in 30-day mortality between RSIE and LSIE (6.9% *vs.* 14.6%, $P=0.373$), whereas 1-year mortality was lower in RSIE compared to LSIE (6.9% *vs.* 26.1%; $P=0.045$). The incidence of postoperative complications, such as re-exploration for bleeding, postoperative stroke, postoperative hemodialysis and tracheostomy did not differ between groups.

Subgroups of patients with RSIE

Characteristics of the subgroups of patients with RSIE are depicted in *Table 4*. IVDU was present as a risk factor in ten

RSIE patients (34.5%). These patients were significantly younger (40.4 ± 7.4 ; $P<0.001$) and had a lower body mass index (BMI) [23.6 (21.5–25.4); $P=0.040$]. IVDU patients presented with more HIV (30% *vs.* 0%; $P=0.008$) and HCV (60% *vs.* 5.3%; $P=0.001$) infection.

Only two patients (6.9%) showed a CIED-related endocarditis. They were significantly older with a mean age of 81.6 ± 3.4 ($P=0.015$). However, due to the small number of patients with CIED, we could not perform a meaningful subgroup analysis of patients with CIED-related RSIE.

Patients without IVDU or CIED presented with more comorbidities, such as diabetes mellitus (23.5% *vs.* 0%; $P=0.030$) and hyperlipidemia (23.5% *vs.* 0%; $P=0.030$). Contrarily to patients with IVDU, most other patients presented with fever (94.1% *vs.* 41.7%; $P=0.001$).

Discussion

The incidence of RSIE compared to LSIE has been reported to be relatively low (1,6). In our IE cohort, only 6.7% underwent cardiac surgery for RSIE. The tricuspid

Table 3 Postoperative outcome of patients undergoing surgery for left- compared to right-sided IE

Variable	All patients (n=432)	LSIE (n=403)	RSIE (n=29)	P value
30-day mortality	61 (14.1)	59 (14.6)	2 (6.9)	0.373
1-year mortality	107 (24.8)	105 (26.1)	2 (6.9)	0.045
Re-exploration for bleeding	70 (16.2)	68 (16.9)	2 (6.9)	0.120
Postoperative stroke	25 (5.8)	25 (6.2)	1 (3.4)	0.545
Postoperative hemodialysis	62 (14.4)	59 (14.6)	3 (10.3)	0.623
Tracheostomy	62 (14.4)	59 (14.6)	3 (10.3)	0.504
Time of ventilation (hours)	21.1 (12.0–87.4)	21.8 (12.0–93.2)	15.8 (9.9–54.3)	0.202
ICU stay (days)	4.0 (2.0–9.0)	4.0 (2.0–9.0)	4.0 (2.0–7.0)	0.500
Hospital stay (days)	12.0 (9.0–17.0)	12.0 (8.0–17.0)	13 (10.0–19.0)	0.310

Data presented as median (IQR) or number (percent), respectively. ICU, intensive care unit; IE, infective endocarditis; LSIE, left-sided infective endocarditis; RSIE, right-sided infective endocarditis.

valve was affected in the majority of RSIE (93.1%), with only two cases (6.9%) of pulmonary valve IE. Compared with LSIE, RSIE is usually associated with a favorable prognosis and low mortality rates (3,17). We observed a 30-day mortality of 6.9% in patients undergoing surgery for RSIE, consistent with previous reports, showing mortality rates ranging from 5% to 12.5% (18,19). However, we could not detect a difference in 30-day mortality. This might be attributed to a high proportion (37.9%) of concomitant LSIE involvement in our RSIE group.

Diagnosis of RSIE is often delayed, since respiratory, rather than systemic signs of IE predominate (1). A variety of complications caused by septic pulmonary emboli have been described, such as pulmonary infarction, pulmonary abscesses, bilateral pneumothoraces, pleural effusions and empyema (9). In line with this, we observed a significantly higher rate of septic pulmonary emboli in patients undergoing surgery for RSIE compared to LSIE (27.6% vs. 1.2%; $P < 0.001$).

The RSIE population can be distinguished by patients with IVDU, implanted cardiac electronic devices and patients with central venous lines or dialysis access (3). IVDU has been described as a leading predisposing factor and accounts for an increasing incidence in developed countries (1,20). There have been reports that 30–40% of all RSIE cases are associated with IVDU (5,21). This is in line with our findings, showing a proportion of 34.5% with IVDU in the RSIE cohort. In contrast, RSIE due to CIED accounts for only 9% in the literature (2,22). Similarly, we

found a rate of 6.9% of CIED-related RSIE.

IVDU patients are more likely to be younger, and their high likelihood of continued drug use is a serious clinical challenge (5). In line with this, we observed that patients in the subgroup with IVDU were significantly younger (40.4 ± 7.4 ; $P < 0.001$) and presented with high rates of HIV (30%) and HCV infection (60%).

Several risk factors for *Staphylococcus aureus* infection in RSIE have been reported, such as higher rates of nasal and cutaneous *Staphylococcus aureus* colonization and contaminated drug use (3,23,24). We found *Staphylococcus aureus* was the most common causative microorganism in the IE cohort, with a significantly higher rate of *Staphylococcus aureus* infection in RSIE compared to LSIE (37.9% vs. 21.1%; $P = 0.035$). These findings are consistent with a previous study by Pfannmueller *et al.* reporting a 43% incidence of *Staphylococcus aureus* infection, followed by coagulase-negative staphylococci and *Enterococcus faecalis* (19). Several risk factors for mortality in patients with RSIE have been described, including *Staphylococcus aureus* infection (5,6,15), fungal etiology or large vegetations (25,26). The presence of large vegetations > 2 cm has been correlated with an increased risk of short- and long-term complications and has been associated with a higher mortality (1,9,25,27). Akinosoglou *et al.* hypothesized that antibiotic penetration is impaired in large vegetations, complicating the eradication of more resistant organisms (1). We found significantly longer vegetations in patients undergoing surgery for RSIE compared to LSIE.

Table 4 Characteristics of subgroups of patients with right-sided IE

Variable	IVDU (n=10)		CIED (n=2)		Other (n=17)	
	n (%)	P value	n (%)	P value	n (%)	P value
Age	40.4±7.4	<0.001	81.6±3.4	0.015	58.3±16.1	0.090
Female sex	4 (40.0)	0.453	1 (50.0)	0.562	4 (23.5)	0.300
BMI	23.6 (21.5–25.4)	0.040	23.9±3.9	0.542	26.6 (23.9–30.3)	0.018
BSA	1.83±0.19	0.141	1.58±0.01	0.059	2.04±0.29	0.014
Hypertension	3 (30.0)	0.362	1 (50.0)	0.799	8 (47.1)	0.458
Diabetes	0 (0)	0.054	0 (0)	0.432	4 (23.5)	0.030
Hyperlipidemia	0 (0)	0.054	0 (0)	0.432	4 (23.5)	0.030
Smoking	4 (40.0)	0.868	1 (50.0)	0.719	6 (35.3)	0.728
COPD	0 (0)	0.099	0 (0)	0.501	3 (17.6)	0.063
Peripheral artery disease	0 (0)	0.460	0 (0)	0.703	1 (5.9)	0.296
Pulmonary hypertension	1 (10.0)	0.965	0 (0)	0.501	2 (11.8)	0.763
Preoperative AKI	4 (40.0)	0.358	2 (100)	0.096	9 (52.9)	0.876
Preoperative stroke	0 (0)	0.184	1 (50.0)	0.072	1 (5.9)	0.799
Coronary artery disease	0 (0)	0.184	1 (50.0)	0.072	1 (5.9)	0.799
Logistic EuroSCORE	3.6 (1.4–6.0)	0.053	16.9±10.1	0.205	6.1 (3.8–17.4)	0.272
EuroSCORE II	4.5 (1.8–6.0)	0.040	9.5±2.1	0.207	6.0 (4.5–10.0)	0.211
History of endocarditis	3 (30.0)	0.008	0 (0)	0.501	0 (0)	0.016
Congenital heart disease	1 (10.0)	0.280	1 (50.0)	0.133	2 (11.8)	0.763
Alcohol abuse	1 (10.0)	0.965	0 (0)	0.501	2 (11.8)	0.763
HIV	3 (30.0)	0.008	0 (0)	0.501	0 (0)	0.016
Active HCV	6 (60.0)	0.001	0 (0)	0.283	1 (5.9)	0.005
Immunosuppression	0 (0)	0.353	0 (0)	0.703	1 (5.9)	0.296
History of neoplasm	0 (0)	0.184	0 (0)	0.586	2 (11.8)	0.134
Septic embolism	1 (10.0)	0.773	1 (50.0)	0.094	7 (41.2)	0.061
Pulmonary focus	2 (20.0)	0.033	0 (0)	0.586	0 (0)	0.053
Fever	3 (30.0)	<0.001	2 (100)	0.246	16 (94.1)	0.001
Vegetation length	2.5±1.30	0.661	2.3±0.83	0.832	2.3±0.64	0.661
Duration preoperative antibiotic therapy	24.0 (5.0–24.0)	0.727	24.0±0	0.833	18.0 (7.8–29.3)	0.570
Days between diagnosis and operation	24.5 (5.8–71.3)	0.443	14.0±14.1	0.513	18.0 (4.0–35.0)	0.719

Data presented as mean ± standard deviation, as median (IQR) or number (percent), respectively. AKI, acute kidney injury; BMI, body mass index; BSA, body surface area; CIED, cardiac implantable electronic device; COPD, chronic obstructive pulmonary disease; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IE, infective endocarditis; IVDU, intravenous drug use.

With increasing experience in cardiac surgery for RSIE, lower or similar in-hospital mortality rates have been described compared to antibiotic therapy alone (5,28). Currently, cardiac surgery for RSIE is suggested in heart failure due to tricuspid valve regurgitation with poor response to medical therapy, tricuspid valve vegetations larger than 2 cm and recurrent emboli despite antimicrobial therapy (15,29,30). Principles of surgery for RSIE include radical debridement of vegetations and infected tissue (10) and valve repair whenever possible (5). Especially in IVDU, valve repair has the advantage of avoiding or minimizing the implantation of foreign material while preserving the function of the valve (9). If the valve is largely destroyed and a replacement is necessary, a bioprosthesis is preferable to a mechanical valve, which requires long-term anticoagulation in patients in whom IVDU is predominant and non-compliance is a major issue (5,10,13,28). Therefore, we suggest that earlier cardiac surgery might prevent further destruction of the leaflets, improve the likelihood of a good repair and decrease RSIE-related mortality by reducing the risk of right heart failure.

Our study has several limitations that need to be considered for the interpretation of the results. First, this is a single-center study with retrospectively collected data for a limited number of patients. Second, although the sample size of our IE cohort appears to be adequate for a single institution IE collective, the number of patients with RSIE is very small due to the low incidence of RSIE. Hence, we could not perform a powerful univariate and multivariable analysis for risk stratification.

In summary, our data indicate that surgery for RSIE can be performed with low operative mortality. However, larger multicenter prospective trials are needed in order to provide more reliable data on the clinical profile and postoperative course of patients undergoing surgery for RSIE.

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Akinosoglou K, Apostolakis E, Marangos M, et al. Native valve right sided infective endocarditis. *Eur J Intern Med* 2013;24:510-9.
2. Naidoo DP. Right-sided endocarditis in the non-drug addict. *Postgrad Med J* 1993;69:615-20.
3. Chahoud J, Sharif Yakan A, Saad H, et al. Right-Sided Infective Endocarditis and Pulmonary Infiltrates: An Update. *Cardiol Rev* 2016;24:230-7.
4. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. *Arch Intern Med* 2002;162:90-4.
5. Hussain ST, Witten J, Shrestha NK, et al. Tricuspid valve endocarditis. *Ann Cardiothorac Surg* 2017;6:255-61.
6. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. *Arch Intern Med* 2009;169:463-73.
7. Fernandez Guerrero ML, Alvarez B, Manzarbeitia F, et al. Infective endocarditis at autopsy: a review of pathologic manifestations and clinical correlates. *Medicine (Baltimore)* 2012;91:152-64.
8. Alexiou C, Langley SM, Stafford H, et al. Surgery for active culture-positive endocarditis: determinants of early and late outcome. *Ann Thorac Surg* 2000;69:1448-54.
9. Moss R, Munt B. Injection drug use and right sided endocarditis. *Heart* 2003;89:577-81.
10. Akinosoglou K, Apostolakis E, Koutsogiannis N, et al. Right-sided infective endocarditis: surgical management. *Eur J Cardiothorac Surg* 2012;42:470-9.
11. Ortiz C, Lopez J, Garcia H, et al. Clinical classification and prognosis of isolated right-sided infective endocarditis. *Medicine (Baltimore)* 2014;93:e137.
12. Musci M, Siniawski H, Pasic M, et al. Surgical treatment of right-sided active infective endocarditis with or without involvement of the left heart: 20-year single center experience. *Eur J Cardiothorac Surg* 2007;32:118-25.
13. Gaca JG, Sheng S, Daneshmand M, et al. Current outcomes for tricuspid valve infective endocarditis surgery in North America. *Ann Thorac Surg* 2013;96:1374-81.
14. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis* 2000;30:633-8.
15. Authors/Task Force M, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European

- Association of Nuclear Medicine (EANM). *Eur Heart J* 2015;36:3075-128.
16. Weber C, Gassa A, Rokohl A, et al. Severity of presentation, not sex, increases risk of surgery for infective endocarditis. *Ann Thorac Surg* 2019;107:1111-7.
 17. Fernandez Guerrero ML, Gonzalez Lopez JJ, Goyenechea A, et al. Endocarditis caused by *Staphylococcus aureus*: A reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. *Medicine (Baltimore)* 2009;88:1-22.
 18. Hilbig A, Cheng A. Infective Endocarditis in the Intravenous Drug Use Population at a Tertiary Hospital in Melbourne, Australia. *Heart Lung Circ* 2019. [Epub ahead of print].
 19. Pfannmueller B, Kahmann M, Davierwala P, et al. Tricuspid Valve Surgery in Patients with Isolated Tricuspid Valve Endocarditis: Analysis of Perioperative Parameters and Long-Term Outcomes. *Thorac Cardiovasc Surg* 2017;65:626-33.
 20. Chambers HF, Morris DL, Tauber MG, et al. Cocaine use and the risk for endocarditis in intravenous drug users. *Ann Intern Med* 1987;106:833-6.
 21. Baraki H, Saito S, Al Ahmad A, et al. Surgical treatment for isolated tricuspid valve endocarditis- long-term follow-up at a single institution. *Circ J* 2013;77:2032-7.
 22. Revilla A, Lopez J, Villacorta E, et al. Isolated right-sided valvular endocarditis in non-intravenous drug users. *Rev Esp Cardiol* 2008;61:1253-9.
 23. Tuazon CU, Sheagren JN. Increased rate of carriage of *Staphylococcus aureus* among narcotic addicts. *J Infect Dis* 1974;129:725-7.
 24. Ortiz-Bautista C, Lopez J, Garcia-Granja PE, et al. Current profile of infective endocarditis in intravenous drug users: The prognostic relevance of the valves involved. *Int J Cardiol* 2015;187:472-4.
 25. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. *Ann Intern Med* 1992;117:560-6.
 26. Martin-Davila P, Navas E, Fortun J, et al. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size. *Am Heart J* 2005;150:1099-106.
 27. Okonta KE, Adamu YB. What size of vegetation is an indication for surgery in endocarditis? *Interact Cardiovasc Thorac Surg* 2012;15:1052-6.
 28. Dawood MY, Cheema FH, Ghoreishi M, et al. Contemporary outcomes of operations for tricuspid valve infective endocarditis. *Ann Thorac Surg* 2015;99:539-46.
 29. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation* 2015;132:1435-86.
 30. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;129:2440-92.

Cite this article as: Weber C, Gassa A, Eghbalzadeh K, Merkle J, Djordjevic I, Maier J, Sabashnikov A, Deppe AC, Kuhn EW, Rahmanian PB, Liakopoulos OJ, Wahlers T. Characteristics and outcomes of patients with right-sided endocarditis undergoing cardiac surgery. *Ann Cardiothorac Surg* 2019;8(6):645-653. doi: 10.21037/acs.2019.08.02